Elevation Point Wealth Partners LLC purchased a new stake in shares of Corteva, Inc. (NYSE:CTVA - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 12,464 shares of the company's stock, valued at approximately $1,056,000.
A number of other hedge funds have also recently modified their holdings of CTVA. Alta Advisers Ltd purchased a new position in Corteva during the second quarter worth about $236,000. Daiichi Life Insurance Co. Ltd. purchased a new stake in shares of Corteva in the 2nd quarter valued at approximately $2,251,000. Commerce Bank purchased a new stake in shares of Corteva in the 2nd quarter valued at approximately $5,208,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Corteva during the 2nd quarter worth approximately $4,381,000. Finally, Evolve Private Wealth LLC purchased a new stake in shares of Corteva during the 2nd quarter valued at approximately $341,000. Hedge funds and other institutional investors own 81.54% of the company's stock.
Corteva Stock Performance
NYSE:CTVA opened at $82.74 on Tuesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.10 and a current ratio of 1.52. The stock has a market capitalization of $55.21 billion, a P/E ratio of 54.80, a PEG ratio of 2.51 and a beta of 0.57. The company has a 50 day moving average price of $82.27 and a 200 day moving average price of $80.32. Corteva, Inc. has a fifty-two week low of $60.53 and a fifty-two week high of $90.97.
Corteva (NYSE:CTVA - Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported $2.30 earnings per share for the quarter, beating the consensus estimate of $2.24 by $0.06. Corteva had a net margin of 5.66% and a return on equity of 10.18%. The firm had revenue of $6.38 billion during the quarter, compared to the consensus estimate of $6.60 billion. During the same quarter last year, the firm earned $2.20 EPS. The firm's revenue for the quarter was down 1.2% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.600-3.800 EPS. Equities research analysts forecast that Corteva, Inc. will post 3.72 EPS for the current year.
Corteva Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Tuesday, September 1st will be paid a $0.18 dividend. The ex-dividend date of this dividend is Tuesday, September 1st. This represents a $0.72 dividend on an annualized basis and a dividend yield of 0.9%. Corteva's payout ratio is presently 47.68%.
Analyst Ratings Changes
CTVA has been the topic of a number of recent analyst reports. Mizuho upped their price objective on Corteva from $96.00 to $97.00 and gave the company an "outperform" rating in a report on Tuesday, July 14th. JPMorgan Chase & Co. raised their target price on Corteva from $77.00 to $83.00 and gave the stock a "neutral" rating in a research note on Monday, August 3rd. UBS Group reduced their target price on Corteva from $89.00 to $85.00 and set a "neutral" rating on the stock in a research report on Tuesday, August 18th. Morgan Stanley upped their price target on Corteva from $84.00 to $95.00 and gave the company an "overweight" rating in a research note on Thursday, May 28th. Finally, Weiss Ratings downgraded Corteva from a "hold (c+)" rating to a "hold (c)" rating in a research report on Monday, August 3rd. Fourteen analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, Corteva presently has a consensus rating of "Moderate Buy" and an average price target of $91.50.
Check Out Our Latest Stock Analysis on CTVA
Corteva Profile
(
Free Report)
Corteva, Inc NYSE: CTVA is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva's operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.
Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Corteva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corteva wasn't on the list.
While Corteva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
